This Year's Highlights

• Results of Centrose technologies were recently reviewed and highlighted in the prestigious Journal Nature: April 26 2007 review article, September 21, 2006 News and Views and a June 28, 2007 highlight.
• Centrose has received a $244,000 Phase I Small Business Innovation Research grant from the National Institutes of Allergy and Infectious Disease to develop new antiinfectives using its proprietary technology.
• Centrose has been certified by the Wisconsin State Department of Commerce as a qualified new business venture. Certification allows early accredited investors the right to earn a 25% tax credit.

Anticipated Highlights

• Centrose has been scored within the approval range for three additional SBIR/STTR Phase I grants and expects funding to begin in early 2008.
• Centrose expects to have its seed round of funding completed in Q4 of 2007 and begin its search for Series A in Q1 2008
• Centrose expects its first lead drug candidate to be optioned to an investment firm for development and trials in early 2008.

Corporate Mission

Centrose is focused on becoming the leader in sugar-enhanced small molecule therapeutic discovery. Centrose will fill voids in its customer's early lead pipelines by providing them with license agreements to new Centrose enhanced drug leads. Centrose will also build credibility and value through partnership deals with strategic players. Partnerships with potential acquisition partners will be focused on resurrecting failing drugs, enhancing existing drugs and providing incremental benefits to drug classes in established markets.
Together with the University of Wisconsin and WARF, Centrose is presently developing novel therapeutics to fight cancer and infective diseases using its proprietary breakthrough sugar chemistries; glycorandomization, neoglycorandomization and sugar pirating.
The Company already has lead compounds that show improvements in safety, potency, selectivity or reduction in side effects due to off-target activities.